Published in Mov Disord on October 30, 2009
The primate thalamostriatal systems: Anatomical organization, functional roles and possible involvement in Parkinson's disease. Basal Ganglia (2011) 0.87
Neuroprotective changes in degeneration-related gene expression in the substantia nigra following acupuncture in an MPTP mouse model of Parkinsonism: Microarray analysis. Genet Mol Biol (2014) 0.81
The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord (2008) 5.72
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Clinicopathological correlates in frontotemporal dementia. Ann Neurol (2004) 4.38
The pathological basis of semantic dementia. Brain (2005) 2.96
Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. Brain (2014) 2.74
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Pedigree with frontotemporal lobar degeneration--motor neuron disease and Tar DNA binding protein-43 positive neuropathology: genetic linkage to chromosome 9. BMC Neurol (2008) 2.34
FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathol (2010) 2.30
Neuropathologic correlates of white matter hyperintensities. Neurology (2008) 2.29
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol (2005) 2.14
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain (2013) 2.09
Use of artificial tanning products among young adults. J Am Acad Dermatol (2006) 1.91
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Cognitive, extrapyramidal, and magnetic resonance imaging predictors of functional impairment in nondemented older community dwellers: the Sydney Older Person Study. J Am Geriatr Soc (2006) 1.63
HDAC5 controls MEF2C-driven sclerostin expression in osteocytes. J Bone Miner Res (2015) 1.60
A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain (2005) 1.57
Small-vessel disease in patients with Parkinson's disease: a clinicopathological study. Mov Disord (2012) 1.56
Progression in frontotemporal dementia: identifying a benign behavioral variant by magnetic resonance imaging. Arch Neurol (2006) 1.47
Maternal birthplace and breastfeeding initiation among term and preterm infants: a statewide assessment for Massachusetts. Pediatrics (2006) 1.44
Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Mov Disord (2013) 1.44
C9ORF72 repeat expansion in clinical and neuropathologic frontotemporal dementia cohorts. Neurology (2012) 1.44
P25alpha immunoreactive but alpha-synuclein immunonegative neuronal inclusions in multiple system atrophy. Acta Neuropathol (2006) 1.43
Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain (2006) 1.43
Cortical limb myoclonus in pathologically proven progressive supranuclear palsy. Mov Disord (2013) 1.39
Clinical significance of lobar atrophy in frontotemporal dementia: application of an MRI visual rating scale. Dement Geriatr Cogn Disord (2007) 1.39
Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain (2002) 1.27
Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol (2008) 1.26
Eating and hypothalamus changes in behavioral-variant frontotemporal dementia. Ann Neurol (2010) 1.24
Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol (2010) 1.21
Presenilin-1 mutation L271V results in altered exon 8 splicing and Alzheimer's disease with non-cored plaques and no neuritic dystrophy. J Biol Chem (2002) 1.19
Regional and cellular pathology in frontotemporal dementia: relationship to stage of disease in cases with and without Pick bodies. Acta Neuropathol (2004) 1.19
α-Synucleinopathy phenotypes. Parkinsonism Relat Disord (2014) 1.16
Quantification and comparison of marijuana smoking practices: blunts, joints, and pipes. Drug Alcohol Depend (2010) 1.15
miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway. Cancer Res (2014) 1.14
Neuron loss from the hippocampus of Alzheimer's disease exceeds extracellular neurofibrillary tangle formation. Acta Neuropathol (2001) 1.12
Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch Neurol (2003) 1.10
Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson's disease. Mov Disord (2002) 1.10
Postmortem analysis of bilateral subthalamic electrode implants in Parkinson's disease. Mov Disord (2002) 1.09
p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol (2007) 1.08
Severity of gliosis in Pick's disease and frontotemporal lobar degeneration: tau-positive glia differentiate these disorders. Brain (2003) 1.06
Visual misperceptions and hallucinations in Parkinson's disease: dysfunction of attentional control networks? Mov Disord (2011) 1.05
Reduced T helper and B lymphocytes in Parkinson's disease. J Neuroimmunol (2012) 1.03
Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease. Acta Neuropathol (2011) 1.03
Distribution of brain atrophy in behavioral variant frontotemporal dementia. J Neurol Sci (2005) 1.02
Impact of attention-deficit hyperactivity disorder and other psychopathology on treatment retention among cocaine abusers in a therapeutic community. Addict Behav (2004) 1.02
Genetic and clinical features of progranulin-associated frontotemporal lobar degeneration. Arch Neurol (2011) 1.01
A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Brain (2005) 0.97
Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease? Mov Disord (2009) 0.97
Lipid pathway alterations in Parkinson's disease primary visual cortex. PLoS One (2011) 0.96
Mutations in the tau gene that cause an increase in three repeat tau and frontotemporal dementia. Brain (2003) 0.95
Clinicopathological staging of frontotemporal dementia severity: correlation with regional atrophy. Dement Geriatr Cogn Disord (2004) 0.95
Reduced mortality associated with breast-feeding-acquired HIV infection and breast-feeding among HIV-infected children in Zambia. J Acquir Immune Defic Syndr (2008) 0.95
Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease. Mov Disord (2007) 0.95
Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J Neuropathol Exp Neurol (2009) 0.95
Variable phenotype of Alzheimer's disease with spastic paraparesis. J Neurochem (2007) 0.94
GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. J Comp Neurol (2012) 0.94
Differences in regional brain atrophy in genetic forms of Alzheimer's disease. Neurobiol Aging (2006) 0.94
In vivo tibial compression decreases osteolysis and tumor formation in a human metastatic breast cancer model. J Bone Miner Res (2013) 0.93
The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease. Hum Brain Mapp (2013) 0.93
A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. Parkinsonism Relat Disord (2004) 0.93
Focal demyelination in Alzheimer's disease and transgenic mouse models. Acta Neuropathol (2010) 0.93
Dolichol is the major lipid component of human substantia nigra neuromelanin. J Neurochem (2005) 0.93
An improved high-throughput lipid extraction method for the analysis of human brain lipids. Lipids (2013) 0.92
Atomoxetine Treatment for Cocaine Abuse and Adult Attention-Deficit Hyperactivity Disorder (ADHD): A Preliminary Open Trial. J Dual Diagn (2009) 0.92
Isoform-specific proteolysis of apolipoprotein-E in the brain. Neurobiol Aging (2009) 0.92
Novel oral drug administration in an animal model of neuroleptic therapy. J Neurosci Methods (2005) 0.91
What is the dominant Abeta species in human brain tissue? A review. Neurotox Res (2005) 0.91
Unique transcriptome patterns of the white and grey matter corroborate structural and functional heterogeneity in the human frontal lobe. PLoS One (2013) 0.91
Low serum progranulin predicts the presence of mutations: a prospective study. J Alzheimers Dis (2010) 0.90
Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy. Mov Disord (2010) 0.89
Regulation of beta-catenin trafficking to the membrane in living cells. Cell Signal (2008) 0.89
Astrocytic degeneration relates to the severity of disease in frontotemporal dementia. Brain (2004) 0.89
Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains. J Neural Transm (Vienna) (2009) 0.89
Use of the narrow beam test in the rat, 6-hydroxydopamine model of Parkinson's disease. J Neurosci Methods (2006) 0.89
The case of a 48 year-old woman with bizarre and complex delusions. Nat Rev Neurol (2010) 0.89
Neurofilament-immunoreactive neurons in Alzheimer's disease and dementia with Lewy bodies. Neurobiol Dis (2002) 0.88
Selective hippocampal neuron loss in dementia with Lewy bodies. Ann Neurol (2002) 0.87
Visual hallucinations in Parkinson's disease: theoretical models. Mov Disord (2014) 0.87
Positional effects of presenilin-1 mutations on tau phosphorylation in cortical plaques. Neurobiol Dis (2004) 0.87
Macroautophagy in sporadic and the genetic form of Parkinson's disease with the A53T α-synuclein mutation. Transl Neurodegener (2012) 0.87
Concurrent cannabis use during treatment for comorbid ADHD and cocaine dependence: effects on outcome. Am J Drug Alcohol Abuse (2006) 0.87
DNA methylation of the MAPT gene in Parkinson's disease cohorts and modulation by vitamin E in vitro. Mov Disord (2013) 0.86
Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients. J Parkinsons Dis (2013) 0.86
Frequency of tau mutations in familial and sporadic frontotemporal dementia and other tauopathies. J Neurol (2004) 0.86
Phosphorylation of apolipoprotein-E at an atypical protein kinase CK2 PSD/E site in vitro. Biochemistry (2005) 0.86
The neural basis of semantic memory: evidence from semantic dementia. Neurobiol Aging (2008) 0.86
Aspects of innate immunity and Parkinson's disease. Front Pharmacol (2012) 0.85
FAS-dependent cell death in α-synuclein transgenic oligodendrocyte models of multiple system atrophy. PLoS One (2013) 0.84
Pathological staging of frontotemporal lobar degeneration. J Mol Neurosci (2011) 0.84
ATP13A2 (PARK9) protein levels are reduced in brain tissue of cases with Lewy bodies. Acta Neuropathol Commun (2013) 0.83
Effect of age on proliferation-regulating factors in human adult neurogenic regions. J Neurochem (2010) 0.83
Cytoskeletal alterations differentiate presenilin-1 and sporadic Alzheimer's disease. Acta Neuropathol (2008) 0.83
Increased expression of ABCA8 in multiple system atrophy brain is associated with changes in pathogenic proteins. J Parkinsons Dis (2013) 0.83
Longitudinal white matter changes in frontotemporal dementia subtypes. Hum Brain Mapp (2013) 0.82
Is seladin-1 really a selective Alzheimer's disease indicator? J Alzheimers Dis (2012) 0.82
Utility and limitations of Addenbrooke's Cognitive Examination-Revised for detecting mild cognitive impairment in Parkinson's disease. Dement Geriatr Cogn Disord (2011) 0.82
Intralaminar nuclei of the thalamus in Lewy body diseases. Brain Res Bull (2008) 0.82
An emerging role for LRRK2 in the immune system. Biochem Soc Trans (2012) 0.82
The relationship between clinical and pathological variables in Richardson's syndrome. J Neurol (2011) 0.81